Published

Drugs in therapy. LSD, MDMA, marijuana, psilocybin, designer drugs and its potential in modern medicine.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Farmacja Polska
Date: 2020-09-28
Source: OpenAlex
DOI: 10.32383/farmpol/127922
PubMed: Unavailable

Authors

Agata Tadeja

Watch author

Derived topics and classifications

psilocybin Pharmacology Receptor Pharmacology Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Drugs in therapy. LSD, MDMA, marijuana, psilocybin, designer drugs and its potential in modern medicine.2020-09-28

Related papers

The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14 Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01 Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord InjuryClinicalTrials.gov · 2026-08-10 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-08-05 Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-02 A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of PsilocybinClinicalTrials.gov · 2026-07-17